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Objectives: The purpose of this study was to assess the magnitude of hypoglycemia 
barrier in terms of physician’s treatment choices and algorithm and the impact of 
hypoglycemia in adherence and persistence to insulin treatment. MethOds: Four 
hundred thirteen Turkish physicians were interviewed by close ended questions 
with a mix of dichotomous or bounded continuous response formats. Questions 
were asked face to face in 2 national diabetes congresses, with a physician mix of 
75% internists, 23% endocrinologists, 1,9% family physicians and rest pediatricians 
and obstetrics. Results: Within 413 replies on how important is the hypoglyce-
mia barrier to reach the target HbA1c on an importance scale, 95% replied either 
important or very important. 82% of physicians declared that they would change 
their target HbA1c, if they were not concerned about hypoglycemia. Similarly, 88% 
of physicians believed more of insulin-treated patients might reach target HbA1c 
if physicians are not concerned about hypoglycemia. Among the physicians replied 
79% stated that less than 40% of their patients reported their hypoglycemic status. 
If patients experience hypoglycemia, 75% of physicians would reduce the insulin 
dose for more than 60% of patients, 85% would stop insulin treatment for less than 
20% of patients, 91% would switch to other insulins and 62% would to prefer to keep 
same treatment for less than 20% of the patients. Among the physicians replied, 
35% of them declared that patients are willing to stop treatment due to hypoglyce-
mia and more than 50% declared that patient needs a new insulin that causes less 
hypoglycemia. cOnclusiOns: In this study, physician dimension of hypoglycemia 
was explored. From the results obtained, it is obvious for the Turkish physicians 
that hypoglycemia is perceived as a major barrier for the better treatment of the 
patients. These results show that new treatment options causing less hypoglycemia 
are needed in the treatment of diabetes mellitus.
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Objectives: The rational treatment of all diseases, but especially a chronic disease 
that have common systemic effects, medium and long-term complications such as 
diabetes is extremely important. The aim of the study is to understand medicine 
utilization in type II diabetes in Turkey. MethOds: In order to examine this topic, 
the volume and costs of anti-diabetics, preference rates of the active substances, 
first prescription behavior of physicians were taken from data base (MEDULA) of 
Social Security Institution, the government based reimbursement agency of Turkey 
from year 2007-2014. Descriptive analysis was conducted. Results: Consumption 
of diabetic medicines rose from 638 million TL to 1.116 million TL between 2007 and 
2013, respectively. The majority of the increase came from insulin and analogs that 
rose from 254 million TL to 664 million TL between 2007 to and 2013, respectively. 
84,17% of naïve diabetic patients had been started with anti(?) diabetic protocols 
without insulin in 2013. In additional, metformin was used as 76,24% of all patients 
in 2013 among them. 65,4% of diabetic patients diagnosed between 40-64 age in 2013. 
Approximately 70% of all patients were diagnosed by internal physicians in 2013, 
that ratio seems grooving in recent years. cOnclusiOns: Diabetic medicines are 
one of the mostly consuming medicines in Turkey. In additional, the consumption of 
diabetic medicines was is rising each every year. Diabetic protocols without insulin 
or including metformin have the highest percentage of all treatment protocols. 
Patients were diagnosed with internal physicians while it was expected as family 
physicians depending on clinical guidelines. The analysis may be a guide for poli-
cymakers to understand how the diabetes is managing in Turkey.
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Objectives: Insulin degludec (IDeg) is a long acting basal insulin analogue used 
once-daily in patients with Type 1 and Type 2 diabetes and was approved for use 
in Europe in 2013. A survey among clinicians was conducted to understand the 
initial real world experience from prescribing IDeg. MethOds: Clinicians with 
experience of prescribing IDeg in Germany, Sweden, Luxembourg, Switzerland 
and United Kingdom were invited to answer a short questionnaire in four waves. 
Collected data reflected the type of patients using IDeg, and the realised benefits 
of treatment including reductions in insulin dosing. Patients were not identifi-
able, and responses were anonymised, and qualitative or quantitative analyses 
used where appropriate. Results: In total, 226 clinicians (n) representing 3,083 
patients (pts) responded. In Germany (n= 201), clinicians reported a slight prefer-
ence to use IDeg for patients with T2DM versus patients with T1DM (34.5% versus 
25.5% respectively, with 35.5% stating T1DM and T2DM). Overall, reported clinical 
benefits included improvement in blood glucose control (n= 93, pts= 1440), flex-
ibility for patients (n= 69; pts= 1072) and reduced risk of hypoglycaemia (n= 55, 
pts= 939). Switching to IDeg allowed dose reductions in most patients (44% (n= 100) 
of clinicians representing 55% (n= 1690) of patients). Overall, 74% of clinicians 
(n= 168; pts= 1,856) reported the flexible dosing schedule had a positive impact on 
patients. cOnclusiOns: These early findings in Germany and other European 
countries confirm the results from IDeg randomised clinical trials and indicate real 
world experience with IDeg is positive for both clinicians and patients by adding 
valuable treatment benefits.
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in Malaysia. Undiagnosed and failure to achieve trio Hs treatment goals further 
increased complication and severity of the chronic conditions. Hyperlipidemia 
was highly underdiagnosed and efforts are needed to manage these conditions 
in holistic manner rather than isolation.
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Objectives: For patients with T2DM does telemedicine, compared with standard 
care, provide equivalent clinical outcomes? MethOds: Forty patients with type 2 
diabetes mellitus allocated from October 2011 until July 2012 randomized to either 
treatment at home by video conferences only or the standard outpatient treatment. 
Primary outcomes were HbA1c and blood glucose levels and secondary outcomes 
were 24-h blood pressure, cholesterol levels, and albuminuria. The videotelephone 
was installed and serviced by the telephone company, TDC, Denmark, as a broadband 
solution. Results: The improvements in the two treatments, given as changes in 
percent of telemedicine vs. standard, showed significant differences in HbA1c (-15 
vs. -11 %), mean blood glucose (-18 vs. -13 %,.and in cholesterol (-7 vs. -6 %). No dif-
ferences in LDL (-4 vs. -6 %), weight (-1 vs. 2 %), diastolic diurnal blood pressure (-1 
vs. -7 %), and systolic diurnal blood pressure (0 vs. -1 %) were found. Nine consulta-
tions were missed in the standard outpatient group and none in the telemedicine 
group. cOnclusiOns: The direct comparison of home video consultations versus 
standard outpatient treatment in T2DM, telemedicine was a safe and superior option 
in treatment of T2DM with equivalent or better outcome after six months treatment.
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Objectives: Diabetic foot ulcer (DFU) is the most serious and disabling long term 
complication of diabetes, adversely affecting the health related quality of life 
(HRQoL). This study evaluates the impact of patient-education on HRQoL of DFU 
patients. MethOds: This open-labeled randomized controlled study on the effect 
of patient-education on improvement of HRQoL, conducted in Kasturba Medical 
College Hospital, Manipal, (coastal South India), consisted of 120 DFU patients with 
60 subjects each in the control group [CG] and intervention group [IG]. RAND-36 
questionnaire was employed for evaluating HRQoL scores of DFU patients in both 
groups at baseline and after six months of educational intervention. Results: 
Subjects in the both IG and CG reported poor HRQoL scores, (similar in each group) 
on all the eight subscales at baseline. But, after six months of educational interven-
tion, HRQoL improved substantially in IG with respect to CG as well as IG at baseline 
(p< 0.05). Likewise, in both CG and IG, the physical component summary scale (PCS) 
scores (22.9±6.4 vs 24.4± 7.6) and the mental component summary scale (MCS) 
scores (26.1±5.2 vs 27.6±7.3) were similar and poor before educational intervention. 
However, six months post educational intervention, in IG, the Both PCS and MCS 
scores increased dramatically from 24.4± 7.6 to 41.8±8.6 and 27.6±7.3 to 47.6±5.6 
(p< 0.05) respectively. cOnclusiOns: The remarkable improvement in the HRQoL 
in IG at six months follow-up suggests that patient-education significantly improves 
HRQoL in DFU patients. Overworked physicians and paucity of trained doctors in 
resource-poor settings obligate task-shifting to non-physician healthcare providers. 
Educational intervention is an economical and feasible strategy, especially in the 
context of the ever-increasing burden of non-communicable disease in resource-
poor developing world.
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Objectives: To give knowledge about diabetes and health, to prevent from diabetes 
employees at Health clinic at Songino khairkhan district. MethOds: Survey card 
with 12 questions has been given to 50 professionals, staff and employees which 
was randomly chosen, agreed to fill out survey and who has never been diagnosed 
with diabetes and working in a shift of health clinic. Blood glucose determination 
and body mass index tools are defined by medical instruments and apparatus. 
Survey was carried out from April, 2014 to July, 2014. Research data and results were 
developed by using the software “SPSS -11.5”. Results: 9 employees (38%) were 
30-39 years of age with an average age of 38.6 ± 9, and 44 of them were (88%) female 
and 24 of them were (48%), non-medical professionals, and 32 of them have never 
been done blood sugar test (64%). DISCUSSION: Our research result was related 
with people’s living condition who uses high calorie food because diabetes research 
of Fukashima, M. &Ogowa, K. (2008) have determined that people in the big cities 
uses high calorie foods, and rich carbohydrates food and have physical inactivity 
comparing with people who are living in the countryside. CONCLUSION: The aver-
age age of respondents were 38.6 ± 9, and 15 of them were 40-49 years old.(30%) 32 
of the employees have never given glucose test before (64%) and 15 of them had 
(30%) glucose monitored with 7.6. And 20 of them had heavy weight (40%), and 26 
of them worked for 24 hours (52%).
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a greater proportion of patients with sustained resolution of heartburn for up 4 
weeks than omeprazole 20 mg (OR= 1.34; 95%CI: 1.09-1.65). The tolerability and 
safety of esomeprazole were comparable to that of other PPIs. cOnclusiOns: 
Esomeprazole proved to be more effective in healing of erosive GERD than the 
other available PPIs.
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Objectives: Effects of malnutrition in patients underwent abdominal resection 
surgery (ARS) are often disregarded. This abstract aims to report nutritional sup-
plement (NS) usage in patients underwent abdominal resection surgery (ARS) for 
non-oncological conditions in Turkey using general health insurance (GHI) reim-
bursement database of Social Security Institute. MethOds: Turkish GHI system 
has covered 98% of total population of Turkey. Therefore statistics obtained via 
the GHI database are highly representative of the population of Turkey. From GHI 
database, patients who underwent any kind of ARS for non-oncological condi-
tions between 1 January 2009 and 31 December 2013 were included to analy-
sis. Results: In GHI database, 5,787 patients (mean age: 55.0 years, 45.6% female) 
met selection criteria of this abstract. NS was used for 6.6% of the patients dur-
ing hospitalization (median 12.0 days) and NS was used median 2.0 days dur-
ing hospitalization. Mortality rate was 24.2% during hospitalization. Of the 4,384 
discharged patients, 1.2% used NS during outpatient follow-up duration and 
0.8% used NS more than 30 days based on prescribing data. Moreover 97.6% of 
patients who received NS during hospitalization did not continue NS usage dur-
ing outpatient follow-up duration. Median survival durations were 60.0 and 25.1 
months in patients not used NS and used NS, and 12-month survival rates were 
65.0% and 51.0%, respectively. cOnclusiOns: The abstract showed NS usage pat-
terns in patients who underwent ARS for non-oncological conditions in Turkey. 
Malnutrition risk increased with ARS due to type of intervention, but ratio of NS 
usage in daily practice is low and usage duration is relatively short. Moreover 
survival analyses revealed that NS seems to be preferred for complicated patients. 
In conclusion all patients underwent ARS should be evaluated for malnutrition 
and treated accordingly to avoid medical and economic burden.
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Objectives: Inflammatory Bowel Diseases (IBD), which include Crohn’s disease and 
Ulcerative Colitis, are chronic and life-long conditions. Only symptomatic reliefs 
exist, because the exact cause is not entirely understood. The aim of this study 
was to analyze the healthcare profile and the overall cost of patients with IBD in 
the real clinical practice. MethOds: From ARNO Observatory database we car-
ried out a record linkage analysis of disease exemptions, drug prescriptions and 
hospital discharges on 2.664.778 subjects, with available, complete and good qual-
ity data. Hospitalizations and specialist services of every single patient with IBD 
were followed up to 3 years after the accrual (from 01/01/2009 to 31/12/2009), while 
pharmaceutical data were collected up to 4 years. All pharmaceutical prescriptions, 
hospital care (re-hospitalizations, gastro-intestinal surgery, in-hospital mortality), 
diagnostic procedures and their costs (mean patient/year) were analyzed. Results: 
25.427 patients with IBD (50,5% female, mean 56,7±18,7 y.o.) received specific drugs: 
intestinal antinflammatory agents (92,4%), intestinal antinfectives/antibacterials 
for systemic use (49,7%) the most prescribed and immunosoppressants the most 
expensive. As non-specific therapy, patients with IBD received Protonic Pomp 
Inhibitors (62,3%) and antibacterials for systemic use (Penicillins – 58%, Macrolides 
– 39% and Quinolones – 35,8%) prescriptions. Focus on hospitalizations revealed: 
cancer chemotherapy was the first cause of day-hospital admissions and the most 
expensive one; 8,4% of patients had cardiovascular comorbidities; the most fre-
quent re-hospitalizations of men aged 15-44 years; the most prevalent in-hospital 
mortality of women aged ≥ 80 years. The 1-year follow-up costs analysis provided 
that hospitalizations were the most expensive (54,4% /total expenditure, mean cost 
1.168€ /patient) and that specific drugs accounted only for the 9,4%. cOnclusiOns: 
In-hospital cares are the main cost driver for patients with IBD. This must be con-
sidered by LHUs and Physicians when evaluating patient healthcare pathways with 
chronic disease and estimating costs of illness. ARNO Observatory represents an 
important tool to support clinical governance.
gAstrointestinAl DisorDers – cost studies
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Objectives: Ulcerative Colitis (UC) exerts significant burden to IBD patients and 
payers. The aim of this study was to estimate the budget impact of vedolizumab in 
moderate/severe UC, from the perspective of the Greek healthcare setting. MethOds: 
A Microsoft Excel-based budget impact model was adapted for a hypothetical cohort 
within the total Greek population of IBD patients with moderate/severe UC. The 
budget impact was calculated and presented as incremental drug-acquisition and 
administration costs (input values obtained from National official databases), before 
and up to three years after the introduction of vedolizumab versus standard of care. 
Objectives: American Diabetes Association and European Association for the 
Study of Diabetes recommend HbA1c levels ≤ 7%, and emphasize initial therapy 
with lifestyle interventions and metformin, addition of medications and transition 
to new regimens within 3-6 months when glycemic goals are not achieved, and 
addition of insulin in patients who remain uncontrolled. This study examines real-
world practice in T2DM patients among US commercially insured patients as it 
relates to guideline recommendations. MethOds: A retrospective analysis using 
Truven Health MarketScan® Research Database identified adult T2DM patients 
from 2006-2012 with a minimum follow-up of one year. Patients were categorized 
based on initial therapy: cohort 1 (n= 597,664) - newly diagnosed without treat-
ment in the year prior to or following diagnosis; cohort 2 (n= 342,511) - oral anti-
diabetic drug (OAD) initiators; cohort 3 (n= 99,578) - basal insulin initiators, and 
cohort 4 (n= 62,876) – prandial/mixed insulin initiators. Patients were followed 
for up to 4 years and transitioned out of a cohort once they met the criteria for 
the next cohort. All data were summarized using descriptive statistics. Results: 
Mean age in cohorts 1-4 were 59.1, 56.2, 57.8, and 59.1 years, with approximately 
equal gender distribution. In cohort 1, average HbA1c remained stable, 6.3%, dur-
ing follow-up. 9% of patients initiated treatment with OADs by year 2, and 19% 
by year 4. Those in cohort 2 not achieving HbA1c ≤ 7%, insulin was infrequently 
initiated; approximately 1% transitioned from OADs to insulin. In cohorts 3 and 
4, despite elevated HbA1c values ≥ 8%, the majority of patients were extensively 
treated with OADs prior to insulin initiation. In cohort 4, 69% of patients were 
using basal insulin at year 1, decreasing to 54% by year 4. cOnclusiOns: Findings 
indicate discrepancies in regimens prescribed to T2DM patients in a real-world 
setting despite guideline recommendations to intensify treatment if patients fail 
to achieve glycemic targets.
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Objectives: As effective management of DM improves clinical outcomes, qual-
ity of care initiatives are being undertaken in many jurisdictions. In the 2012 
Canadian Community Health Survey (CCHS), data were collected on healthcare 
received by those with DM. The objective was to characterize the demographics 
of, and care received by, a contemporary population of adult Canadians with DM; 
and assess whether care quality varied according to age or sex. MethOds: Data 
from the subset of 2012 CCHS adult respondents (n= 61,707) asked about diabetes 
care were analyzed. Demographic and clinical characteristics were tabulated, and 
respondents classified as receiving quality diabetic care if they had HbA1c or foot 
exams during the past year, and retinal exams within two years. Predictors of 
receiving quality care were explored using logistic regression, and the frequency 
of physician visits and hospitalizations compared between those receiving, or 
not receiving, quality care. Results: Of the diabetes care cohort (n= 2,458), 48% 
were male, and 75.1% were ≥ 60 years. Eighty percent had a recent HbA1c test, and 
69.2% and 55.2% had a recent eye or foot exam, respectively. Thirty-eight percent 
reported receiving quality diabetes care. While results were similar by sex, some 
variability was observed by age. The percentage receiving quality care ranged from 
30.4% (≥ 80 years), to 40.1% (60-80 years). Age was the only significant predictor; 
the odds of receiving quality care were lower among those aged ≥ 80 years. The fre-
quency of physician visits and hospitalizations did not vary according to receipt of 
quality care. cOnclusiOns: While some guideline monitoring was conducted for 
most respondents, less than half reported receiving all aspects of recommended 
diabetes care. Because these data were self-reported, respondents may have 
received recommended evaluations but been unaware. Opportunities may there-
fore exist for improving the diabetic care of patients, and their awareness of that 
care.
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Objectives: An 8-week course of proton pump inhibitors (PPIs) is the therapy of 
choice for the treatment of gastroesophageal reflux disease (GERD). Esomeprazole, 
the S-isomer of omeprazole, seems to have more potent acid suppression com-
pared to other PPIs due to improved pharmacokinetic profile. The aim of the 
current systematic review was to identify consistent evidence of differences in 
efficacy between esomeprazole and the other available PPIs. MethOds: A lit-
erature search of Medline, Embase and Cochrane Library was conducted (last 
search 8/2014) to identify randomized clinical trials comparing rates of endo-
scopic healing and heartburn resolution with esomeprazole versus other PPIs 
(i.e. lansoprazole, omeprazole and pantoprazole) in the treatment of GERD. Search 
and selection of the studies was performed independently by two researchers. 
Only intention-to-treat population reported data were analyzed. Results: Twelve 
RCT studies (3 vs omeprazole, 3 vs lansoprazole and 6 vs pantoprazole) met the 
inclusion criteria and were included in the systematic review. Almost all identi-
fied studies had low or moderate risk of bias (Jadad scale ranging 3-5). One study 
had high risk of bias. The analysis comparing esomeprazole 40 mg with lanso-
prazole 30 mg showed a significant difference in endoscopic healing rate in favor 
of esomeprazole at 4 weeks (OR= 1.25; 95%CI: 1.12-1.40) and 8 weeks (OR= 1.29; 
95%CI: 1.13-1.48). Similarly, esomeprazole 40 mg demonstrated significantly higher 
healing rate when was compared with pantoprazole 40 mg at 4 weeks (OR= 1.33; 
95%CI: 1.15-1.52) and with omeprazole 20 mg at 8 weeks (OR= 1.56; 95%CI: 1.08-
2.25). Data from meta-analysis indicated that esomeprazole 40 mg provided also 
